Cancer metastases: Challenges and opportunities

Acta Pharmaceutica Sinica B

Volumn 5, Issue 5, 2015, Pages 402-418

  Guan, Xiangming ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Adhesion; Cancer; Detachment; Invasion; Metastasis; Migration

Indexed keywords

BOSUTINIB; BRIVANIB ALANINATE; CADHERIN; CEP 751; CHEMOKINE; CILENGITIDE; DASATINIB; DOXAZOSIN; ERLOTINIB; GEFITINIB; GROWTH FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN; IMMUNOTOXIN; INTEGRIN; METALLOPROTEINASE; MICRORNA; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; ORANTINIB; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEINASE; RECOMBINANT HYALURONIDASE; SARACATINIB; SELECTIN; SORAFENIB; SUNITINIB; SURAMIN; TERAZOSIN;

ANOIKIS; CANCER CELL LINE; CELL ACTIVITY; CELL ADHESION; CELL DETACHMENT; CELL MIGRATION; CELL MOTILITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84947201969     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2015.07.005     Document Type: Review

References (119)

1. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013, 18:43-73.
2. Damsky WE, Theodosakis N, Bosenberg M. Melanoma metastasis: new concepts and evolving paradigms. Oncogene 2014, 33:2413-2422.
3. Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2013, 34:283-289.
4. Weber GF. Why does cancer therapy lack effective anti-metastasis drugs?. Cancer Lett 2013, 328:207-211.
5. Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol 2012, 727:186-198.
6. Daenen LGM, Roodhart JML, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res 2011, 71:6976-6985.
7. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
8. Haraguchi M. The role of the transcriptional regulator snail in cell detachment, reattachment and migration. Cell Adhes Migr 2009, 3:259-263.
9. Zanotti S, Gibertini S, Bragato C, Mantegazza R, Morandi L, Mora M. Fibroblasts from the muscles of Duchenne muscular dystrophy patients are resistant to cell detachment apoptosis. Exp Cell Res 2011, 317:2536-2547.
10. Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Asp Med 2010, 31:205-214.
11. Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumour Biol 2014, 35:8483-8523.
12. Profumo V, Gandellini P. MicroRNAs: cobblestones on the road to cancer metastasis. Crit Rev Oncog 2013, 18:341-355.
13. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat 2011, 128:7-21.
14. Bravo-Cordero JJ, Hodgson L, Condeelis JS. Spatial regulation of tumor cell protrusions by RhoC. Cell Adhes Migr 2014, 8:263-267.
15. White DE, Muller WJ. Multifaceted roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007, 12:135-142.
16. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004, 90:561-565.
17. Janik ME, Lityńska A, Vereecken P. Cell migration-the role of integrin glycosylation. Biochim Biophys Acta 2010, 1800:545-555.
18. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 2008, 8:377-386.
19. Schlaepfer DD, Jones KC, Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol 1998, 18:2571-2585.
20. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996, 85:683-693.
21. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997, 110:2473-2482.
22. Rivard N. Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function. Front Biosci (Landmark Ed) 2009, 14:510-522.
23. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann NY Acad Sci 2004, 1014:155-163.
24. Jiang WG. E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg 1996, 83:437-446.
25. Pećina-Šlaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003, 3:17.
26. Riethmacher D, Brinkmann V, Birchmeier C. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci U S A 1995, 92:855-859.
27. Luo J, Lubaroff DM, Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999, 59:3552-3556.
28. Hsu MY, Meier FE, Nesbit M, Hsu JY, van Belle P, Elder DE, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000, 156:1515-1525.
29. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003, 22:6524-6536.
30. Larue L, Antos C, Butz S, Huber O, Delmas V, Dominis M, et al. A role for cadherins in tissue formation. Development 1996, 122:3185-3194.
31. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000, 148:779-790.
32. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999, 147:631-644.
33. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012, 2012:676731.
34. Barclay AN. Membrane proteins with immunoglobulin-like domains-a master superfamily of interaction molecules. Semin Immunol 2003, 15:215-223.
35. Wai Wong C, Dye DE, Coombe DR. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol 2012, 2012:340296.
36. Johnson JP, Bar-Eli M, Jansen B, Markhof E. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer 1997, 73:769-774.
37. Wu GJ, Wu MWH, Wang CS, Liu Y. Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. J Urol 2011, 185:1504-1512.
38. Zeng GF, Cai SX, Wu GJ. Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells. BMC Cancer 2011, 11:113.
39. Roland CL, Harken AH, Sarr MG, Barnett CC ICAM-1 expression determines malignant potential of cancer. Surgery 2007, 141:705-707.
40. Siesser PF, Maness PF. L1 cell adhesion molecules as regulators of tumor cell invasiveness. Cell Adhes Migr 2009, 3:275-277.
41. Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 2006, 12:BR263-BR273.
42. Gavert N, Ben-Shmuel A, Raveh S, Ben-Zeev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008, 8:1749-1757.
43. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 2009, 10:445-457.
44. Underhill C. CD44: the hyaluronan receptor. J Cell Sci 1992, 103:293-298.
45. Shimizu Y, van Seventer GA, Siraganian R, Wahl L, Shaw S. Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol 1989, 143:2457-2463.
46. Trochon V, Mabilat C, Bertrand P, Legrand Y, Smadja-Joffe F, Soria C, et al. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer 1996, 66:664-668.
47. Webb DS, Shimizu Y, van Seventer GA, Shaw S, Gerrard TL. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990, 249:1295-1297.
48. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994, 54:4539-4546.
49. Richter U, Wicklein D, Geleff S, Schumacher U. The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol 2012, 137:687-695.
50. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45.
51. Ishii S, Ford R, Thomas P, Nachman A, Steele G, Jessup JM. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg Oncol 1993, 2:255-264.
52. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992, 116:817-825.
53. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997, 71:241-319.
54. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004, 35:211-231.
55. Legg JW, Lewis CA, Parsons M, Ng T, Isacke CM. A novel PKC-regulated mechanism controls CD44-ezrin association and directional cell motility. Nat Cell Biol 2002, 4:399-407.
56. Lokeshwar VB, Bourguignon LY. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J Biol Chem 1991, 266:17983-17989.
57. Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res 2010, 3:1-7.
58. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61:1303-1313.
59. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010, 46:1271-1277.
60. Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer 2014, 14:632-641.
61. Kirfel G, Rigort A, Borm B, Herzog V. Cell migration: mechanisms of rear detachment and the formation of migration tracks. Eur J Cell Biol 2004, 83:717-724.
62. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol 2012, 22:234-249.
63. Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 2015, 3:4.
64. Paz H, Pathak N, Yang J. Invading one step at a time: the role of invadopodia in tumor metastasis. Oncogene 2014, 33:4193-4202.
65. Wolf K, Friedl P. Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis 2009, 26:289-298.
66. Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 2008, 68:7247-7249.
67. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010, 8:629-642.
68. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014, 16:717-727.
69. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T. Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis 2014, 7:9-18.
70. Naora H. Heterotypic cellular interactions in the ovarian tumor microenvironment: biological significance and therapeutic implications. Front Oncol 2014, 4:18.
71. Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 2014, 40:558-566.
72. Bournazou E, Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT 2013, 2:e23828.
73. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 2013, 73:4965-4977.
74. Chou J, Shahi P, Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013, 12:3262-3271.
75. Zhang Y, Yang PY, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol 2014, 24:153-160.
76. Jiang WG, Ablin RJ. Cancer metastasis, challenges, progress and the opportunities. Front Biosci (Elite Ed) 2011, 3:391-394.
77. Xue CS, Wyckoff J, Liang FB, Sidani M, Violini S, Tsai KL, et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006, 66:192-197.
78. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003, 22:309-325.
79. Aguiar DP, de Farias GC, de Sousa EB, de Mattos Coelho-Aguiar J, Lobo JC, Casado PL, et al. New strategy to control cell migration and metastasis regulated by CCN2/CTGF. Cancer Cell Int 2014, 14:61.
80. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45 Suppl 2:S163-S175.
81. Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003, 190:105-112.
82. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006, 238:30-41.
83. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
84. Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012, 181:1895-1899.
85. Rawlings ND, Barrett AJ. Families of serine peptidases. Methods Enzymol 1994, 244:19-61.
86. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003, 22:237-258.
87. Duffy MJ, OGrady P, Devaney D, OSiorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988, 62:531-533.
88. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005, 94:374-388.
89. Keledjian K, Kyprianou N. Anoikis induction by quinazoline based α1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of Bcl-2. J Urol 2003, 169:1150-1156.
90. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Res 2005, 65:11230-11235.
91. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, et al. Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005, 65:2251-2259.
92. Zhang Y, Fujiwara Y, Doki Y, Takiguchi S, Yasuda T, Miyata H, et al. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Oncology 2008, 75:17-26.
93. Tanaka K, Mohri Y, Nishioka J, Kobayashi M, Ohi M, Miki C, et al. Neurotrophic receptor, tropomyosin-related kinase B as an independent prognostic marker in gastric cancer patients. J Surg Oncol 2009, 99:307-310.
94. Desmet CJ, Peeper DS. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?. Cell Mol Life Sci 2006, 63:755-759.
95. Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, et al. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer 1997, 72:673-679.
96. Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Investig New Drugs 2004, 22:449-458.
97. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010, 36:492-500.
98. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333.
99. Blaschuk OW, Sullivan R, David S, Pouliot Y. Identification of a cadherin cell adhesion recognition sequence. Dev Biol 1990, 139:227-229.
100. Blaschuk OW. Discovery and development of N-cadherin antagonists. Cell Tissue Res 2012, 348:309-313.
101. Russo MA, Paolillo M, Sanchez-Hernandez Y, Curti D, Ciusani E, Serra M, et al. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int J Oncol 2013, 42:83-92.
102. Ganguly KK, Pal S, Moulik S, Chatterjee A. Integrins and metastasis. Cell Adhes Migr 2013, 7:251-261.
103. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investig New Drugs 2012, 30:749-757.
104. Stoeltzing O, Liu WB, Reinmuth N, Fan F, Parry GC, Parikh AA, et al. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003, 104:496-503.
105. Khalili P, Arakelian A, Chen GP, Plunkett ML, Beck I, Parry GC, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006, 5:2271-2280.
106. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000, 60:309-320.
107. Läubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010, 20:169-177.
108. Borsig L, Vlodavsky I, Ishai-Michaeli R, Torri G, Vismara E. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia 2011, 13:445-452.
109. DArena G, Calapai G, Deaglio S. Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. Expert Opin Ther Pat 2014, 24:821-828.
110. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target 2012, 20:561-573.
111. Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep 2014, 8:1558-1570.
112. Revach OY, Geiger B. The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion. Cell Adhes Migr 2014, 8:215-225.
113. Omidi Y, Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts 2014, 4:55-67.
114. Gao F, Liang B, Reddy ST, Farias-Eisner R, Su XL. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets 2014, 14:30-45.
115. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 2014, 6:1670-1690.
116. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014, 2014:149185.
117. Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Semin Nucl Med 2015, 45:110-121.
118. Barar J, Omidi Y. Dysregulated pH in tumor microenvironment checkmates cancer therapy. Bioimpacts 2013, 3:149-162.
119. Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 2014, 4:195.